Vaccine Adjuvants

Transduced Dendritic Cells Inspire Antitumor Effect

Published in Vaccine Weekly, January 9th, 2002

by Sonia Nichols, senior medical writer - A growing body of evidence continues to point to transduced dendritic cells as important adjuvants for tumor vaccines.

"Gene delivery to dendritic cells provides an intracellular source of antigen for efficient and persistent loading to MHC class I molecules capable of activating CD8⁺ CTLs, which play a central role in antitumor immunity," N. Okada and colleagues, Kyoto Pharmaceutical University, Japan, described in a recent report.

To date, attempts at efficient dendritic cell transduction have met with many failures and some successes. Okada and colleagues have performed research suggesting the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-01-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry